J Viral Hepat
- MOHAREB, A. M.
- KOUAME, Menan Gerard
- GABASSI, A.
- GABILLARD, Delphine
- MOH, Desmorys Raoul
- BADJE, Anani Dodzi
- EMIEME, A.
- MAYLIN, S.
- MENAN, H.
- HYLE, E. P.
- DELAUGERRE, C.
- DANEL, Christine
- ANGLARET, Xavier
- LACOMBE, K.
- EHOLIE, Serge Paul
- BOYD, A.
DOIAbstract
BACKGROUND: It is unknown how past and active hepatitis B virus (HBV) infection affect immunorecovery and mortality in people with HIV who initiate tenofovir-based anti-retroviral therapy (ART). METHODS: Using data collected between 2008- 2015, we studied people with HIV in sub-Saharan Africa initiating immediate ART in the Temprano randomized control trial. We classified participants into HBV groups at ART-initiation: hepatitis B surface antigen (HBsAg)-positive with HBV DNA ≥2000 IU/mL; HBsAg-positive with HBV DNA <2000 IU/ml; isolated HBcAb-positive; resolved infection (HBsAb-positive/HBcAb-positive); and HBV non-immune/vaccinated (HBcAb-). We compared square-root CD4-cell count increases using a mixed-effect, non-linear regression adjus...
Add to ORKG